Publications 2023

4. Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: The ESSENTIAL study.

François B, Lambden S, Garaud JJ, Derive M, Grouin JM, Asfar P, Darreau C, Mira JP, Quenot JP, Lemarié J, Mercier E, Lacherade JC, Vinsonneau C, Fivez T, Helms J, Badie J, Levy M, Cuvier V, Salcedo-Magguilli M, Laszlo-Pouvreau AL, Laterre PF, Gibot S.

eClinical Medicine. 2023 ; doi:https://doi.org/10.1016/j.eclinm.2023.102013

IF:15.1

Voir l'article

Prospective evaluation of the efficacy, safety, and the optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock: results of the ASTONISH Phase 2b randomized controlled trial.

François B, Lambden S, Fivez T, Gibot S, Derive M, Grouin JM, Salcedo-Magguilli M, Lemarié J, De Schryver N, Jalkanen Ville, Hicheur T, Garaud JJ, Cuvier V, Ferrer R, Bestle M, Pettilä V, Mira JP, Bouisse C, Mercier E, Vermassen J, Huberlant V, Vinatier I, Anguel N, Levy M, Laterre PF.

The Lancet Respiratory Medicine. 2023 ;

IF:76.2

Voir l'article

14.11. Long-term immunosuppressive treatment is not associated with worse outcome in patients hospitalized in the intensive care unit for septic shock: the PACIFIC study.

Vaidie J, Peju E, Jandeaux LM, Lesouhaitier M, Lacherade JC, Guillon A, Wittebole X, Asfar P, Evrard B, Daix T, Vignon P, François B.

Critical Care. 2023 ; doi: 10.1186/s13054-023-04626-z.

IF:15.1

Voir l'article

23.20. Hydrocortisone in Severe Community-Acquired Pneumonia (CAPE-COD Study).

Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, Reignier J, Heming N, Plantefève G, Souweine B, Voiriot G, Colin G, Frat JP, Mira JP, Barbarot N, François B, Louis G, Gibot S, Guitton C, Giacardi C, Hraiech S, Vimeux S, L'Her E, Faure H, Herbrecht JE, Bouisse C, Joret A, Terzi N, Gacouin A, Quentin C, Jourdain M, Leclerc M, Coffre C, Bourgoin H, Lengellé C, Caille-Fénérol C, Giraudeau B, Le Gouge A; CRICS-TriGGERSep Network.

The New England Journal of Medicine. 2023 ; doi: 10.1056/NEJMoa2215145.

IF:158.5

Voir l'article

Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial (ECULISHU Study).

Garnier A, Brochard K, Kwon T, Sellier-Leclerc AL, Lahoche A, Launay EA, Nobili F, Caillez M, Taque S, Harambat J, Michel-Bourdat G, Guigonis V, Fila M, Cloarec S, Djamal-Dine D, de Parscaux L, Allard L, Salomon R, Ulinski T, Frémeaux-Bacchi V, Morin C, Olivier-Abbal P, Colineaux H, Auriol F, Arnaud C, Kieffer I, Brusq C.

Journal of the American Society of Nephrology. 2023 ; doi: 10.1681/ASN.0000000000000182.

IF:13.6

Voir l'article

+33(0)5 55 05 69 83

secretariat.cic@chu-limoges.fr

2 Av. Martin Luther King, Limoges

PUBLICATIONS

2025 - 2024 - 2023 - 2022

4. Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: The ESSENTIAL study.

Prospective evaluation of the efficacy, safety, and the optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock: results of the ASTONISH Phase 2b randomized controlled trial.

14.11. Long-term immunosuppressive treatment is not associated with worse outcome in patients hospitalized in the intensive care unit for septic shock: the PACIFIC study.

23.20. Hydrocortisone in Severe Community-Acquired Pneumonia (CAPE-COD Study).

Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial (ECULISHU Study).